Novel anticancer activity of phloroglucinol against breast cancer stem-like cells

Toxicology and Applied Pharmacology

Volumn 286, Issue 3, 2015, Pages 143-150

  Kim, Rae Kwon ^a   Uddin, Nizam ^a   Hyun, Jin Won ^b   Kim, Changil ^c   Suh, Yongjoon ^a   Lee, Su Jae ^a  

^a Hanyang University   (South Korea)

^b Jeju National University   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

Anticancer activity; Breast cancer stem like cells; KRAS; Phloroglucinol; Relapse; Resistance to anticancer treatment

Indexed keywords

BETA CATENIN; CISPLATIN; ETOPOSIDE; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH2 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; PHLOROGLUCINOL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; TRANSCRIPTION FACTOR SOX2; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BROWN ALGA; CANCER STEM CELL; CARCINOGENICITY; CELL POPULATION; COLONY FORMATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL DEATH; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; MCF 7 CELL LINE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

PHAEOPHYCEAE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DEATH; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; PHLOROGLUCINOL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937966554     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.03.026     Document Type: Article

References (52)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. 2003, 100:3983-3988.
3. Alpsoy A., Yasa S., Gunduz U. Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms. Biomed. Pharmacother. 2014, 68:351-355.
4. Balko J.M., Schwarz L.J., Bhola N.E., Kurupi R., Owens P., Miller T.W., Gomez H., Cook R.S., Arteaga C.L. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 2013, 73:6346-6358.
5. Becher O.J., Holland E.C. Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. EMBO J. 2014, 33:1984-1986.
6. Bertucci F., Finetti P., Rougemont J., Charafe-Jauffret E., Cervera N., Tarpin C., Nguyen C., Xerri L., Houlgatte R., Jacquemier J., Viens P., Birnbaum D. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005, 65:2170-2178.
7. Bhola N.E., Balko J.M., Dugger T.C., Kuba M.G., Sánchez V., Sanders M., Stanford J., Cook R.S., Arteaga C.L. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest. 2013, 123:1348-1358.
8. Chang H.Y., Nuyten D.S., Sneddon J.B., Hastie T., Tibshirani R., Sorlie T., Dai H., He Y.D., van't Veer L.J., Bartelink H., van de Rijn M., Brown P.O., van de Vijver M.J. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3738-3743.
9. Dontu G., El-Ashry D., Wicha M.S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 2004, 15:193-197.
10. Farnie G., Clarke R.B. Mammary stem cells and breast cancer - role of Notch signalling. Stem Cell Rev. 2007, 3:169-175.
11. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10:R25.
12. Grimshaw M.J., Cooper L., Papazisis K., Coleman J.A., Bohnenkamp H.R., Chiapero-Stanke L., Taylor-Papadimitriou J., Burchell J.M. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res. 2008, 10:R52.
13. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
14. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., Nobel A., Parker J., Ewend M.G., Sawyer L.R., Wu J., Liu Y., Nanda R., Tretiakova M., Ruiz Orrico A., Dreher D., Palazzo J.P., Perreard L., Nelson E., Mone M., Hansen H., Mullins M., Quackenbush J.F., Ellis M.J., Olopade O.I., Bernard P.S., Perou C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
15. Hyun K.H., Yoon C.H., Kim R.K., Lim E.J., An S., Park M.J., Hyun J.W., Suh Y., Kim M.J., Lee S.J. Eckol suppresses maintenance of stemness and malignancies in glioma stem-like cells. Toxicol. Appl. Pharmacol. 2011, 254:32-40.
16. Kang K.A., Lee K.H., Chae S., Zhang R., Jung M.S., Ham Y.M., Baik J.S., Lee N.H., Hyun J.W. Cytoprotective effect of phloroglucinol on oxidative stress induced cell damage via catalase activation. J. Cell. Biochem. 2006, 97:609-620.
17. Kang K.A., Zhang R., Chae S., Lee S.J., Kim J., Kim J., Jeong J., Lee J., Shin T., Lee N.H., Hyun J.W. Phloroglucinol (1,3,5-trihydroxybenzene) protects against ionizing radiation-induced cell damage through inhibition of oxidative stress in vitro and in vivo. Chem. Biol. Interact. 2010, 185:215-226.
18. Koo B.S., Lee S.H., Kim J.M., Huang S., Kim S.H., Rho Y.S., Bae W.J., Kang H.J., Kim Y.S., Moon J.H., Lim Y.C. Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells. Oncogene 2014, [Epub ahead of print]. 10.1038/onc.2014.174.
19. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., Clouthier S.G., Wicha M.S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7:e1000121.
20. Kwok J.M., Peck B., Monteiro L.J., Schwenen H.D., Millour J., Coombes R.C., Myatt S.S., Lam E.W. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res. 2010, 8:24-34.
21. Lai D., Ho K.C., Hao Y., Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 2011, 71:2728-2738.
22. Leis O., Eguiara A., Lopez-Arribillaga E., Alberdi M.J., Hernandez-Garcia S., Elorriaga K., Pandiella A., Rezola R., Martin A.G. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012, 31:1354-1365.
23. Liu S., Dontu G., Wicha M.S. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005, 7:86-95.
24. Liu C.G., Lu Y., Wang B.B., Zhang Y.J., Zhang R.S., Lu Y., Chen B., Xu H., Jin F., Lu P. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann. Surg. 2011, 253:1165-1171.
25. Lu F., Wong C.S. A clonogenic survival assay of neural stem cells in rat spinal cord after exposure to ionizing radiation. Radiat. Res. 2005, 163:63-71.
26. Manuel Iglesias J., Beloqui I., Garcia-Garcia F., Leis O., Vazquez-Martin A., Eguiara A., Cufi S., Pavon A., Menendez J.A., Dopazo J., Martin A.G. Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One 2013, 8:e77281.
27. Marotta L.L., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., Bloushtain-Qimron N., Kim J.J., Choudhury S.A., Maruyama R., Wu Z., Gonen M., Mulvey L.A., Bessarabova M.O., Huh S.J., Silver S.J., Kim S.Y., Park S.Y., Lee H.E., Anderson K.S., Richardson A.L., Nikolskaya T., Nikolsky Y., Liu X.S., Root D.E., Hahn W.C., Frank D.A., Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121:2723-2735.
28. + CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol. Immunother. 2009, 58:1185-1194.
29. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
30. Morrison B.J., Schmidt C.W., Lakhani S.R., Reynolds B.A., Lopez J.A. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res. 2008, 10:210.
31. + cells to blame?. Breast Cancer Res. 2010, 12:105.
32. O'Brien C.A., Kreso A., Jamieson C.H. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010, 16:3113-3120.
33. Petersen O.W., Polyak K. Stem cells in the human breast. Cold Spring Harb. Perspect. Biol. 2010, 2:a003160.
34. + breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 2006, 98:1777-1785.
35. Piva M., Domenici G., Iriondo O., Rabano M., Simoes B.M., Comaills V., Barredo I., Lopez-Ruiz J.A., Zabalza I., Kypta R., Vivanco M. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol. Med. 2014, 6:66-79.
36. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., Daidone M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65:5506-5511.
37. Price J.E. Clonogenicity and experimental metastatic potential of spontaneous mouse mammary neoplasms. J. Natl. Cancer Inst. 1986, 77:529-535.
38. Printz C. Radiation treatment generates therapy-resistant cancer stem cells from less aggressive breast cancer cells. Cancer 2012, 118:3225.
39. Putman D.L., Park D.K., Rhim J.S., Steuer A.F., Ting R.C. Correlation of cellular aggregation of transformed cells with their growth in soft agar and tumorigenic potential. Exp. Biol. Med. 1977, 155:487-494.
40. Segrelles C., Garcia-Escudero R., Garin M.I., Aranda J.F., Hernandez P., Ariza J.M., Santos M., Paramio J.M., Lorz C. Akt signaling leads to stem cell activation and promotes tumor development in epidermis. Stem Cells 2014, 32:1917-1928.
41. Singh I.P., Sidana J., Bharate S.B., Foley W.J. Phloroglucinol compounds of natural origin: synthetic aspects. Nat. Prod. Rep. 2010, 27:393-416.
42. Smith L., Welham K.J., Watson M.B., Drew P.J., Lind M.J., Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol. Res. 2007, 16:497-506.
43. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lonning P.E., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10869-10874.
44. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., Martiat P., Fox S.B., Harris A.L., Liu E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10393-10398.
45. Stockler M., Wilcken N.R., Ghersi D., Simes R.J. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat. Rev. 2000, 26:151-168.
46. Takebe N., Ivy S.P. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin. Cancer Res. 2010, 16:3106-3112.
47. Tsai Y.H., VanDussen K.L., Sawey E.T., Wade A.W., Kasper C., Rakshit S., Bhatt R.G., Stoeck A., Maillard I., Crawford H.C., Samuelson L.C., Dempsey P.J. ADAM10 regulates Notch function in intestinal stem cells of mice. Gastroenterology 2014, 147:822-834.
48. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
49. Wang J., Cao M.G., You C.Z., Wang C.L., Liu S.L., Kai C., Dou J. A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer. Cell. Mol. Biol. 2012, (58 Suppl.):Ol1641-Ol1645. (Noisy-le-Grand, France).
50. Wang Z., Wang N., Li W., Liu P., Chen Q., Situ H., Zhong S., Guo L., Lin Y., Shen J., Chen J. Caveolin-1 mediates chemoresistance in breast cancer stem cells via beta-catenin/ABCG2 signaling pathway. Carcinogenesis 2014, 35:2346-2356.
51. Wu, Y., Wang, Y., Yang, Xiuwei H., Kang, T., Zhao, Y., Wang, C., Evers, B.M., Zhou, Binhua P., The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep. 5, 2013, 224-236.
52. Zheng M., Zhou Y., Yang X., Tang J., Wei D., Zhang Y., Jiang J.L., Chen Z.N., Zhu P. High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients. Breast Cancer Res. Treat. 2014, 148:423-436.